[DICER1 constitutional pathogenic variant syndrome: Where are we in 2019?]

Syndrome associé aux variants pathogènes constitutionnels de DICER1 : Où en sommes-nous en 2019 ?
Children Conseil génétique DICER1 Dépistage Enfant Genetic counseling Ovarian Sertoli-Leydig tumor Pleuropneumoblastoma Pleuropneumoblastomes Rare tumors Screening Surveillance Tumeur ovarienne de Sertoli-Leydig Tumeurs rares

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 24 03 2019
revised: 09 08 2019
accepted: 14 08 2019
pubmed: 16 10 2019
medline: 18 12 2019
entrez: 16 10 2019
Statut: ppublish

Résumé

Inactivating germline pathogenic variants of the DICER1 gene are responsible for a spectrum of rare diseases, which expanded a lot in recent years. The constitution of an U.S. registry with these patients and their families as well as the registration of patients in European databases of rare tumors helped to better identify diseases encountered in this syndrome but also to study its pathophysiology (major role in miRNA maturation and recently discovered functions, e.g. in genome integrity maintenance). Most encountered disorders are pediatric malignancies, mainly the pulmonary pneumoblastoma and Sertoli-Leydig tumours. However, benign pathologies such as thyroid goiters, cystic nephromas or pulmonary cystic lesions are also frequently reported. Homogeneous guidelines regimens written by the European groups working on very rare pediatric tumors are proposed but it is important to underscore that they rely on rare scientific data; therefore overall consensus remains precarious. The genetic counseling to families is still difficult due to the large observed spectrum of tumors and the incomplete penetrance. In this article, the authors update current knowledge on the DICER1 syndrome.

Identifiants

pubmed: 31610911
pii: S0007-4551(19)30332-7
doi: 10.1016/j.bulcan.2019.08.016
pii:
doi:

Substances chimiques

DICER1 protein, human EC 3.1.26.3
Ribonuclease III EC 3.1.26.3
DEAD-box RNA Helicases EC 3.6.4.13

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

1177-1189

Informations de copyright

Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Yves Réguerre (Y)

Centre Hospitalo-Universitaire de Saint Denis, service d'oncologie et d'hématologie pédiatrique, 97400 La Réunion, France. Electronic address: yves.reguerre@chu-reunion.fr.

Lisa Golmard (L)

Institut Curie, service de génétique, 75005 Paris, France.

Hervé J Brisse (HJ)

Institut Curie, université Paris Sciences et Lettres, département d'imagerie, 26, rue d'Ulm Paris, 75005 Paris, France.

Isabelle Oliver Petit (I)

Hôpital des enfants, unité d'endocrinologie, génétique, maladies osseuses et gynécologie de l'enfant, TSA 70034, 31059 Toulouse Cedex, France.

Frédérique Savagner (F)

Hôpital Purpan, biologie moléculaire endocrinienne, service de biochimie, IFB, TSA 40031, 31059 Toulouse cedex, France.

Sabah Boudjemaa (S)

Hôpital d'enfants Armand Trousseau-assistance publique, service d'anatomie et de cytologie pathologiques, 75012 Paris, France.

Marion Gauthier-Villars (M)

Institut Curie, service de génétique oncologique, 75005 Paris, France.

Julien Rod (J)

Université de Caen, département de chirurgie pédiatrique, 14000 Caen, France; Université de Caen Basse-Normandie, UFR Médecine, 14000 Caen, France.

Brice Fresneau (B)

Université Paris-Saclay, Gustave Roussy, département d'oncologie pédiatrique, 94805 Villejuif, France; Inserm, université Paris-Sud Paris-Saclay, CESP, 94805 Villejuif, France.

Daniel Orbach (D)

Institut Curie, PSL université, Centre oncologie SIREDO (Soins, innovation recherche en oncologie de l'enfant, l'adolescent et du jeune adulte), 75005 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH